CPH vs. RX, NINE, TGOD, HEXO, WMD, CWEB, CRDL, VIR, ZOM, and IN
Should you be buying Cipher Pharmaceuticals stock or one of its competitors? The main competitors of Cipher Pharmaceuticals include BioSyent (RX), Delta 9 Cannabis (NINE), Green Organic Dutchman (TGOD), HEXO (HEXO), WeedMD (WMD), Charlotte's Web (CWEB), Cardiol Therapeutics (CRDL), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), and InMed Pharmaceuticals (IN). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Cipher Pharmaceuticals vs.
Cipher Pharmaceuticals (TSE:CPH) and BioSyent (CVE:RX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
Cipher Pharmaceuticals has a net margin of 128.83% compared to BioSyent's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 51.73% beat BioSyent's return on equity.
In the previous week, BioSyent had 10 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 10 mentions for BioSyent and 0 mentions for Cipher Pharmaceuticals. BioSyent's average media sentiment score of 0.58 beat Cipher Pharmaceuticals' score of 0.00 indicating that BioSyent is being referred to more favorably in the news media.
Cipher Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, BioSyent has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.
Cipher Pharmaceuticals received 82 more outperform votes than BioSyent when rated by MarketBeat users. However, 66.20% of users gave BioSyent an outperform vote while only 62.41% of users gave Cipher Pharmaceuticals an outperform vote.
0.2% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.3% of BioSyent shares are owned by institutional investors. 42.7% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 40.6% of BioSyent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Cipher Pharmaceuticals has higher earnings, but lower revenue than BioSyent. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.
Summary
Cipher Pharmaceuticals and BioSyent tied by winning 8 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cipher Pharmaceuticals Competitors List